Technical Analysis for CNTX - Context Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| 20 DMA Support | Bullish | -9.73% | |
| MACD Bearish Signal Line Cross | Bearish | -9.95% | |
| Crossed Above 20 DMA | Bullish | -9.95% | |
| Hammer Candlestick | Bullish | -9.95% | |
| NR7 | Range Contraction | -9.95% | |
| Overbought Stochastic | Strength | -9.95% | |
| Fell Below 20 DMA | Bearish | -8.59% | |
| Stochastic Sell Signal | Bearish | -8.59% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 9 hours ago |
| Down 1% | about 9 hours ago |
| 20 DMA Support | 3 days ago |
| Down 3% | 3 days ago |
| Hammer Candlestick Entry | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/08/2024
Context Therapeutics Inc. Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. Context Therapeutics Inc. has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. The company was founded in 2015 and is based in Philadelphia, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Organ Systems Treatment Of Cancer Breast Cancer Antineoplastic Drugs Endocrine System Cancer Therapeutics Antiprogestogens Estranes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.24 |
| 52 Week Low | 0.77 |
| Average Volume | 892,309 |
| 200-Day Moving Average | 1.30 |
| 50-Day Moving Average | 1.82 |
| 20-Day Moving Average | 1.97 |
| 10-Day Moving Average | 2.05 |
| Average True Range | 0.18 |
| RSI (14) | 42.53 |
| ADX | 18.27 |
| +DI | 18.70 |
| -DI | 22.66 |
| Chandelier Exit (Long, 3 ATRs) | 1.69 |
| Chandelier Exit (Short, 3 ATRs) | 1.90 |
| Upper Bollinger Bands | 2.25 |
| Lower Bollinger Band | 1.69 |
| Percent B (%b) | 0.21 |
| BandWidth | 28.38 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.07 |
| MACD Histogram | -0.0275 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.13 | ||||
| Resistance 3 (R3) | 2.16 | 2.09 | 2.07 | ||
| Resistance 2 (R2) | 2.09 | 2.01 | 2.07 | 2.05 | |
| Resistance 1 (R1) | 1.95 | 1.96 | 1.92 | 1.92 | 2.04 |
| Pivot Point | 1.88 | 1.88 | 1.86 | 1.86 | 1.88 |
| Support 1 (S1) | 1.74 | 1.80 | 1.71 | 1.71 | 1.58 |
| Support 2 (S2) | 1.67 | 1.75 | 1.65 | 1.57 | |
| Support 3 (S3) | 1.53 | 1.67 | 1.55 | ||
| Support 4 (S4) | 1.50 |
